Natera, Inc.

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
91.5 ^USD	+0.51%		+1.30%	+46.07%

Apr. 18	Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	MT
Apr. 18	Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	MT

NATERA, INC. : Regulation FD Disclosure (form 8-K)

March 13, 2023 at 06:05 am EDT

Item 7.01. Regulation FD Disclosure.

Natera, Inc. informs its investors that it does not hold cash deposits or securities with Silicon Valley Bank.

Latest news about Natera, Inc.

Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	Apr. 18	MT
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	Apr. 18	MT
Goldman Sachs Adjusts Natera Price Target to $100 From $90, Maintains Buy Rating	Apr. 15	MT
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	Apr. 11	CI
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	Apr. 08	CI
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	Apr. 05	MT
Bernstein Upgrades Natera to Outperform From Market Perform, Raises Price Target to $120 From $86	Apr. 05	MT
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing	Apr. 05	MT
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	Apr. 01	CI
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer	Mar. 18	CI
Natera Insider Sold Shares Worth $534,331, According to a Recent SEC Filing	Mar. 08	MT
Natera Insider Sold Shares Worth $824,092, According to a Recent SEC Filing	Mar. 08	MT
Natera Insider Sold Shares Worth $16,694,485, According to a Recent SEC Filing	Mar. 08	MT
Natera Receives Commercial Insurance Coverage of Genetic Test for Transplant Risks	Mar. 07	MT
Piper Sandler Raises Natera's Price Target to $110 From $70, Maintains Overweight Rating	Mar. 06	MT
Transcript : Natera, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-06-2024 09:50 AM	Mar. 06
Transcript : Natera, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 02:15 PM	Mar. 05
Natera Insider Sold Shares Worth $4,478,268, According to a Recent SEC Filing	Mar. 01	MT
UBS Adjusts Natera Price Target to $104 From $70, Maintains Buy Rating	Feb. 29	MT
Canaccord Genuity Adjusts Price Target on Natera to $100 From $87, Maintains Buy Rating	Feb. 29	MT
Natera Narrows Q4 Loss, Revenue Rises; Shares Rise Late as 2024 Revenue Outlook Beats Consensus	Feb. 28	MT
Transcript : Natera, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (NTRA) NATERA Posts Q4 Revenue $311.1M, vs. Street Est of $287.3M	Feb. 28	MT
Natera Guides For 2024 Revenue of $1.32-$1.35 Billion, vs CIQ Analyst Consensus of $1.27 Billion	Feb. 28	MT

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Sector

Healthcare Facilities & Services

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Natera, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

91.5 USD

Average target price

103.1 USD

Spread / Average Target

+12.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
NATERA, INC.	+46.07%	11.05B
CVS HEALTH CORPORATION	-14.17%	85.42B
HCA HEALTHCARE, INC.	+17.86%	84.38B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.39B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.51%	17.49B
FRESENIUS SE & CO. KGAA	-2.60%	16.44B
QUEST DIAGNOSTICS INCORPORATED	-0.24%	15.28B
EUROFINS SCIENTIFIC SE	-3.90%	11.71B
FRESENIUS MEDICAL CARE AG	+2.13%	12.22B
PURE HEALTH HOLDING	-30.88%	11.98B

Other Healthcare Facilities & Services

Natera, Inc.

Equities

NTRA

US6323071042

Healthcare Facilities & Services

NATERA, INC. : Regulation FD Disclosure (form 8-K)

Latest news about Natera, Inc.

Chart Natera, Inc.

Company Profile

Income Statement Evolution

Ratings for Natera, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services